A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)

Brief description of study

The purpose of this clinical research study is to learn more about the use of the study drug, volixibat, for the treatment of pruritus (itching) associated with PSC.

Volixibat is an experimental treatment, meaning that it has not been approved by the US Food and Drug Administration (FDA) or any worldwide regulatory body. Volixibat is a drug that lowers circulating bile acid levels that are believed to lead to the itching in patients with PSC. There are no other approved drugs to treat itching in patients with PSC. This is the first time volixibat will be used in patients with PSC.

Clinical Study Identifier: s20-01067
ClinicalTrials.gov Identifier: NCT04663308
Principal Investigator: Ira M. Jacobson.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.